Sun, Jan 25, 2015, 1:23 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Aastrom Biosciences, Inc. Message Board

  • hwmccusker hwmccusker Dec 12, 2012 10:05 AM Flag

    New CEO

    The Bottom Line: Interim CEO, Dan Orlando brings a depth of experience in the development and commercialization of cardiovascular and metabolic therapies that will help ASTM to continue moving forward. Mr. Mayleben will continue to support the transition to a permanent CEO. I am not the only one to say – “Great Move”; Steve Brozak of WBB Securities also signaled the same message in a call … “Dan past deal structure successes and experience should further focus … ASTM’s ability to drive significant value to this disease state franchise”! ASTM closed DOWN yesterday … at $1.30 but, is up $0.02 to $1.32 at the open with a tighter mid-day range of $1.29 – $1.32 but, is settling at $1.30. I have NOT given up as ASTM has been getting “hammered” on filings of stock sales but, they are … related to the warrant swaps … which other companies have been … unable … to recognize with their “muddied” balance sheets! I have maintained a “BUY” in this market and at this pricing because of the late stage trial status even with a dwindling RegMed universe pricing and visibility. As the BOD … fulfills its responsibility … they will make this appointment permanent in the New Year !

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.7650.000(0.00%)Nov 24 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.